How to Get Repatha (Evolocumab) in Minnesota

What Is Repatha and Why Would a Minnesota Physician Prescribe It?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab keeps more LDL receptors active, which drives circulating LDL-C out of the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 remains the landmark outcomes study. Patients on evolocumab 140 mg every two weeks or 420 mg monthly achieved a 59% reduction in LDL-C from baseline compared with placebo, translating into a 15% relative risk reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or coronary revascularization (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). [2] That absolute risk reduction of 1.5 percentage points over 2.2 years is meaningful for high-risk patients who cannot reach guideline-recommended LDL-C targets on statins alone.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that for patients with very high-risk ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence A). [3] That language directly supports the prior authorization arguments Minnesota prescribers make on behalf of their patients every day.

Minnesota has roughly 45,000 residents living with familial hypercholesterolemia based on population-prevalence estimates from the FH Foundation (1 in 250 for HeFH), yet the vast majority remain undiagnosed or undertreated. [4] Evolocumab fills a genuine clinical gap for those patients.

Who Can Prescribe Repatha in Minnesota?

Any Minnesota-licensed prescriber with DEA registration can write for Repatha. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Minnesota does not restrict PCSK9 inhibitor prescribing to cardiologists or lipidologists, though many insurers request a specialist note during prior authorization.

Under Minnesota Statutes Chapter 147A and Chapter 148, NPs with prescriptive authority and PAs working under a collaborative agreement with a supervising physician may independently prescribe schedule and non-schedule medications including Repatha. [5] A primary care physician who identifies elevated LDL-C and documents statin failure or intolerance has full prescribing authority without a mandatory cardiology referral, though a referral often speeds prior authorization approval.

Telehealth providers licensed in Minnesota carry the same prescribing authority as in-person clinicians under Minnesota Statutes Section 147.037, provided they conduct an appropriate clinical evaluation. [6] That evaluation must include a documented medical history, review of current medications, and a laboratory basis for the prescription (typically a fasting lipid panel drawn within the preceding 12 months). A video or asynchronous chart review satisfies Minnesota's telehealth standard of care when the provider documents the encounter thoroughly.

How to Get a Repatha Prescription in Minnesota: Step-by-Step

Getting Repatha in Minnesota follows a predictable sequence regardless of whether you see a provider in person or via telehealth.

Step 1: Confirm your eligibility with lab work. A fasting lipid panel is the minimum required. Most insurers also want LFTs (to rule out active liver disease), and some require a creatine kinase (CK) level to document statin myopathy if that is the basis for statin intolerance. Order these through your primary care physician, a Quest or LabCorp draw site available in all major Minnesota metro areas including Minneapolis, Saint Paul, Rochester, Duluth, and Mankato, or through a telehealth platform that arranges lab orders directly. [7]

Step 2: Schedule a provider visit. In-person options include cardiologists affiliated with Mayo Clinic in Rochester, Allina Health, M Health Fairview, HealthPartners, or Sanford Health clinics in the southern and western parts of the state. Telehealth options include platforms licensed in Minnesota that staff cardiologists and internal medicine physicians who specialize in lipid disorders. Video visits typically run 20 to 30 minutes. The provider will review your lipid history, statin trial documentation, and cardiovascular risk.

Step 3: Receive the prescription and initiate prior authorization. The prescribing provider or their staff submits a prior authorization (PA) request to your insurer. See the prior authorization section below for specifics. Most Minnesota commercial insurers resolve PA requests within 3 to 14 business days. Minnesota Medicaid (Medical Assistance) covers evolocumab with PA for both FH and established ASCVD. [8]

Step 4: Specialty pharmacy fulfillment. Once PA is approved, the prescription routes to a specialty pharmacy. Amgen's patient support program (Repatha by Amgen) works with CVS Specialty, Accredo, Walgreens Specialty, and other contracted pharmacies. Most Minnesota residents receive their first shipment within 7 to 10 days of PA approval. Cold-chain shipping is standard because evolocumab must be refrigerated (36 to 46 degrees Fahrenheit). [9]

Step 5: Learn injection technique. Repatha comes as a 140 mg/mL prefilled SureClick autoinjector or a prefilled syringe. The 420 mg monthly dose uses a Pushtronex on-body infusor. Your specialty pharmacy or provider will supply injection training materials, and Amgen offers a nurse educator program for in-home training at no cost through the Repatha Support program. [10]

What Labs Are Needed Before Starting Repatha in Minnesota?

A fasting lipid panel is the non-negotiable baseline. Clinicians also typically order a complete metabolic panel including liver function tests (AST, ALT, total bilirubin, albumin) because active liver disease is a relative contraindication. If a patient is documenting statin myopathy as the reason for statin failure, a baseline CK level strengthens both the clinical record and the PA submission.

The ACC/AHA guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiating a PCSK9 inhibitor to confirm therapeutic response, then every 3 to 12 months thereafter. [3] Minnesota commercial insurers often require documentation of that follow-up lipid panel for continuation authorization, so scheduling it in advance saves time.

For patients being evaluated for familial hypercholesterolemia specifically, the Dutch Lipid Clinic Network (DLCN) score uses LDL-C level, personal and family cardiovascular history, physical findings (tendon xanthomas, corneal arcus), and genetic testing results. [11] Genetic testing for LDLR, APOB, and PCSK9 mutations is available through Mayo Clinic Laboratories in Rochester and through several commercial labs that ship kits to Minnesota addresses. A confirmed pathogenic variant in one of those genes qualifies a patient for the HeFH or HoFH label that carries the strongest PA approval rate across Minnesota insurers.

Additional labs that some cardiologists order before initiating evolocumab include Lp(a) (lipoprotein(a)), which is elevated in approximately 20% of FH patients and may independently predict cardiovascular risk, and a thyroid panel to rule out hypothyroidism as a secondary cause of hypercholesterolemia. [12]

Prior Authorization Requirements for Repatha in Minnesota

Prior authorization is the most common barrier Minnesota patients face. Understanding exactly what insurers want makes the process faster.

Most Minnesota commercial plans (BlueCross BlueShield of Minnesota, HealthPartners, UCare, Medica, PreferredOne) require documentation of the following before approving evolocumab:

1. A diagnosis of HeFH, HoFH, or established ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization).
2. A baseline LDL-C at or above 70 mg/dL for ASCVD patients, or at or above 100 mg/dL for FH patients, despite maximally tolerated statin therapy.
3. A documented trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) at the maximum tolerated dose, typically for 90 days or more.
4. For statin-intolerant patients: documentation of two separate statin trials resulting in myopathy, elevated CK, or other documented adverse effects, along with a CK or liver enzyme result supporting intolerance.
5. A trial of ezetimibe 10 mg daily (most plans now require this as a step therapy before approving a PCSK9 inhibitor).

The ACC/AHA 2022 cholesterol guideline explicitly states: "For patients with clinical ASCVD at very high risk, if the LDL-C level remains 70 mg/dL or higher after maximally tolerated statin therapy and ezetimibe, a PCSK9 inhibitor is recommended." [3] Quoting that language verbatim in a PA letter significantly improves approval odds.

Minnesota Medicaid (Medical Assistance) follows a similar step therapy protocol. The Minnesota Department of Human Services publishes a preferred drug list (PDL) that places evolocumab in a specialty tier requiring PA. [8] Approval is routinely granted when the documentation package is complete. Appeals for denied PA requests in Minnesota must follow the Minnesota Department of Commerce timeline: initial determination within 3 business days for urgent cases or 14 calendar days for standard requests.

Telehealth Options for Getting Repatha Prescribed in Minnesota

Minnesota law explicitly permits telehealth prescribing for non-controlled medications including evolocumab. A provider practicing in Minnesota (or a provider in another state holding a Minnesota medical license) can evaluate a patient via video, review their lipid history and labs, and issue a Repatha prescription without an in-person visit. [6]

Several national telehealth platforms staff licensed Minnesota prescribers for lipid management. The visit workflow typically looks like this: the patient completes an intake form documenting their cardiovascular history, current medications, and prior statin trials; uploads their most recent fasting lipid panel results; and then joins a video call with the clinician. If the clinical picture supports evolocumab, the provider submits the prescription and initiates PA through the platform's care coordination team.

The telehealth route is particularly valuable for patients in Greater Minnesota, where access to cardiologists and lipidologists is limited. Rochester and the Twin Cities metro have strong specialty lipid programs, but patients in Bemidji, International Falls, Worthington, or the Iron Range may face waits of weeks to months for an in-person cardiology appointment. A telehealth visit can be scheduled in days. [13]

One practical note: the specialty pharmacy that ultimately fulfills a Repatha prescription must be licensed in Minnesota or must hold a Minnesota non-resident pharmacy license if shipping from out of state. The Minnesota Board of Pharmacy maintains a searchable licensure database confirming which specialty pharmacies are authorized to ship to Minnesota addresses. [14]

503A Compounding Pharmacies and Evolocumab in Minnesota

Minnesota is one of the states that permits 503A compounding pharmacies to prepare evolocumab formulations for patients with documented individual clinical needs that cannot be met by the commercially available Repatha product. A 503A pharmacy (as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act) may compound evolocumab when a licensed Minnesota prescriber provides a valid patient-specific prescription. [15]

This matters for a small subset of patients who have documented allergies to an excipient in the branded Repatha product, who require a dose or concentration not commercially available, or whose insurance denies coverage and who are paying out of pocket at a lower compounded cost. 503A compounding is patient-specific and requires a prescription for each individual; it is not bulk manufacturing.

The Minnesota Board of Pharmacy licenses 503A compounding pharmacies and conducts inspections aligned with USP Chapter 797 standards for sterile compounding, since evolocumab is administered subcutaneously. [14] Patients considering a compounded evolocumab formulation should confirm their chosen pharmacy holds current Minnesota licensure and a sterile compounding accreditation from PCAB (Pharmacy Compounding Accreditation Board) or an equivalent body.

How Long Does It Take to Receive Repatha After Seeing a Doctor in Minnesota?

The total timeline from initial provider visit to first injection has several distinct components. The provider visit itself takes 1 to 3 days to schedule through telehealth, or 1 to 8 weeks for an in-person cardiology appointment in the Twin Cities and longer in rural areas.

Lab work, if not already available, adds 1 to 5 business days depending on the draw site and whether results are faxed or transmitted electronically to the prescriber.

Prior authorization adds the largest variable: 3 to 14 business days for most Minnesota commercial plans under standard review. Urgent PA requests for patients with recent ACS or stroke may be resolved in 24 to 72 hours. If the initial PA is denied and an appeal is filed, Minnesota law requires a decision within 30 days for standard appeals. [16]

Specialty pharmacy processing and cold-chain shipping from the fulfillment center to a Minnesota address typically takes 2 to 5 business days once PA is approved and the copay situation is resolved.

Realistic total timelines:

• Best case (labs already available, telehealth visit, rapid PA approval): 7 to 10 days.
• Typical case (labs needed, in-person visit, standard PA): 3 to 5 weeks.
• Worst case (denied PA, appeal required, rural area): 6 to 10 weeks.

Amgen's Repatha Support program offers a 30-day free trial for commercially insured patients while PA is pending, which means eligible Minnesota patients may start therapy before their insurer renders a final decision. [10]

Transferring an Existing Repatha Prescription to Minnesota

Patients relocating to Minnesota who are already established on evolocumab have two straightforward options. First, their current out-of-state specialty pharmacy may hold a Minnesota non-resident pharmacy license and can continue shipping without any change. The patient should call the pharmacy to confirm Minnesota licensure before assuming continuity.

Second, the patient can request a transfer of the prescription to a Minnesota-licensed specialty pharmacy. A transferred prescription for a non-controlled substance like evolocumab is valid as long as the original prescription has refills remaining and the prescribing provider is still licensed. [17] If the original provider is not licensed in Minnesota, the patient needs a new evaluation from a Minnesota-licensed provider, but the clinical record and prior authorization history from the previous state can be submitted to support a rapid new PA approval.

Minnesota does not require a new in-state PA when a patient transfers an existing prescription and changes only the dispensing pharmacy, provided the patient's Minnesota insurer has its own PA on file. Patients switching insurance upon moving to Minnesota will almost always need a new PA regardless of prior approvals in another state.

Cost and Savings Programs for Minnesota Patients

The list price for Repatha is approximately $7,200 per year, though virtually no commercially insured patient pays that amount. Amgen's copay card reduces out-of-pocket costs to as low as $5 per month for eligible commercially insured patients. [10]

For uninsured or underinsured Minnesota residents, Amgen's patient assistance program (Repatha Enrollment Center) provides evolocumab at no cost to patients meeting income eligibility criteria (generally at or below 600% of the federal poverty level). [10] Minnesota also has the Minnesota Prescription Drug Program, a state-administered discount program available to all Minnesota residents regardless of income, which negotiates reduced prices on specialty drugs including PCSK9 inhibitors. [18]

Medicare Part D covers evolocumab under specialty tier formulary placement. Minnesota Medicare beneficiaries enrolled in a Part D plan should review their plan's formulary and step therapy requirements, as these vary by plan. The Medicare Extra Help (Low Income Subsidy) program significantly reduces specialty tier cost-sharing for qualifying beneficiaries. [19]

Monitoring After Starting Repatha in Minnesota

Once therapy begins, the prescribing clinician should check a fasting lipid panel 4 to 12 weeks after the first injection to confirm the expected LDL-C reduction of approximately 59% from baseline. [2] If the response is substantially less than expected, the clinician should review injection technique, storage conditions (evolocumab must remain refrigerated and not be frozen), and medication adherence.

Long-term safety data from the FOURIER Open Label Extension (FOURIER-OLE), which followed patients for a median of 5 years, showed no new safety signals and a continued reduction in cardiovascular events with sustained LDL-C lowering. [20] Liver enzyme elevations, muscle symptoms, and diabetes incidence were not significantly different from placebo in FOURIER (N=27,564), supporting long-term tolerability. [2]

The ACC recommends annual fasting lipid panels and periodic reassessment of cardiovascular risk for patients on PCSK9 inhibitor therapy. [3] Minnesota prescribers can manage this monitoring through primary care, avoiding the need for ongoing specialty visits once therapy is stabilized.

Injection site reactions occur in approximately 3.2% of patients in clinical trials, are generally mild and transient, and rarely require discontinuation. [21] Patients should rotate injection sites (abdomen, thigh, or upper arm) with each dose.